Cargando…

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine

BACKGROUND: To review the distribution and function of K(ATP) channels, describe the use of K(ATP) channels openers in clinical trials and make the case that these channels may play a role in headache and migraine. DISCUSSION: K(ATP) channels are widely present in the trigeminovascular system and pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Karagholi, Mohammad Al-Mahdi, Hansen, Jakob Møller, Severinsen, Johanne, Jansen-Olesen, Inger, Ashina, Messoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567577/ https://www.ncbi.nlm.nih.gov/pubmed/28831746 http://dx.doi.org/10.1186/s10194-017-0800-8

Ejemplares similares

The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2022)

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
por: Thuraiaiyah, Janu, et al.
Publicado: (2022)

Involvement of Potassium Channel Signalling in Migraine Pathophysiology
por: Al-Karagholi, Mohammad Al-Mahdi
Publicado: (2023)

The ATP sensitive potassium channel (K(ATP)) is a novel target for migraine drug development
por: Clement, Amalie, et al.
Publicado: (2023)

Pharmacological Profiling of K(ATP) Channel Modulators: An Outlook for New Treatment Opportunities for Migraine
por: Dyhring, Tino, et al.
Publicado: (2023)

ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential
por: Clement, Amalie, et al.
Publicado: (2022)

The Effect of K(ATP) Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers
por: Coskun, Hande, et al.
Publicado: (2021)

Debate: Are cluster headache and migraine distinct headache disorders?
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2022)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Brain barriers and their potential role in migraine pathophysiology
por: Wiggers, Astrid, et al.
Publicado: (2022)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2021)

Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Correction: Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2023)

Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial
por: Pellesi, Lanfranco, et al.
Publicado: (2021)

Correction to: Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

The chronobiology of migraine: a systematic review
por: Poulsen, Amanda Holmen, et al.
Publicado: (2021)

Targeting Peripheral N-Methyl-D-Aspartate Receptor (NMDAR): A Novel Strategy for the Treatment of Migraine
por: Kalatharan, Veberka, et al.
Publicado: (2023)

Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura
por: Antonova, M, et al.
Publicado: (2013)

Imaging the inflammatory phenotype in migraine
por: Christensen, Rune Häckert, et al.
Publicado: (2022)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence
por: Raffaelli, Bianca, et al.
Publicado: (2023)

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
por: Karlsson, William Kristian, et al.
Publicado: (2023)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2022)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Pathophysiology of migraine
por: Goadsby, Peter J.
Publicado: (2012)

Correction: PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2023)

Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial
por: Kokoti, Lili, et al.
Publicado: (2023)

Involvement of gap junction channels in the pathophysiology of migraine with aura
por: Sarrouilhe, Denis, et al.
Publicado: (2014)

Migraine and cluster headache – the common link
por: Vollesen, Anne Luise, et al.
Publicado: (2018)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n9e3v1jic9b4qo2h5oiq57d1p2